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Heart Failure, Atrial Fibrillation,
and Catheter Ablation
Are We There Yet?*
Mark D. O’Neill, MB BCH BAO DPHIL
London, United Kingdom
Contemporary cardiological practice places great emphasis
on the availability of an evidence base to justify and refine
indications for treatment. This is particularly apposite to
the field of catheter ablation for atrial fibrillation (AF), where
almost 2 decades of research at an increasingly frenetic pace has
delivered us a potentially curative treatment in carefully se-
lected patients. In drug refractory patients, there is now
consensus that catheter ablation is recommended in paroxys-
mal AF, reasonable in persistent AF, and might be considered
in longstanding persistent AF (1,2). It is also deemed reason-
able to consider catheter ablation in all AF patient groups
before a trial of drug therapy (2).
See page 1894
Heart failure (HF) and AF are often referred to as the
twin epidemics of cardiovascular disease and frequently
coexist in the same patient. Robust epidemiological and
pathophysiological evidence clearly implicates AF in the
development and/or exacerbation of left ventricular dys-
function, whereas conversely, HF promotes atrial electrical
and structural change that serves to facilitate the perpetua-
tion of AF, once initiated. For the arrhythmia, the therapeu-
tic goal would seem self-evident—to seek to prevent or reverse
the development of AF in all patients with HF and in
particular in those for whom no identifiable cause has been
found. Nevertheless, well-designed and executed studies of
rhythm versus rate control therapy in normal left ventricular
function (3) and HF patients (4) have not demonstrated an
important advantage in favor of the former, citing the potential
dangers of antiarrhythmic medication as a sink for any bene-
ficial effect of sinus rhythm restoration. It is against this
heartscape that many electrophysiologists see a potentially key
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There are precious few prospective randomized con-
trolled trials in the field of AF ablation, with our practice
influenced greatly by well-executed cohort experiences in
patients with HF, many of which demonstrate a positive
impact of catheter ablation on outcome measures such as
ejection fraction (5). The 3 randomized studies that do exist
offer starkly different experiences—Hsu et al. (6) demon-
strated convincingly that AF ablation resulted in a remark-
able improvement in ejection fraction; Khan et al. (7)
demonstrated superiority of ablation over atrioventricular
node ablation and biventricular pacing in a mixed paroxys-
mal and persistent AF population when using a composite
endpoint of ejection fraction, 6-min walk distance, and
Minnesota Living with Heart Failure Questionnaire score;
whereas a more recent smaller study by MacDonald et al. (8)
did not show any impact on magnetic resonance-derived
ejection fraction, N-terminal pro–B-type natriuretic pep-
tide, 6-min walk, or quality of life.
In this issue of the Journal, Jones et al. (9) report their
ndings from a single center, prospective randomized trial of
atheter ablation versus stringent rate control in an HF
opulation with persistent AF. Over almost 4 years, they were
ble to randomize 52 patients who met the demanding
nclusion criteria of persistent AF, New York Heart Associa-
ion functional class II to IV symptoms on a regimen of
ptimal HF therapy, and left ventricular ejection fraction
35%, while excluding patients with cardiovascular implant-
ble electronic device insertion within 6 months. In addition to
onventional cohort characterization measures, the investiga-
ors included B-type natriuretic peptide, radionuclide ventricu-
ography, cardiopulmonary exercise testing, Minnesota Living
ith Heart Failure Questionnaire score, and a 6-min walk test.
ate control was achieved in 88% of patients by 3 months, and
4 of 26 patients in the rate control group remained in AF
hroughout the study, representing a true test of rhythm versus
ate control. Although a stepwise catheter ablation strategy was
mployed, the rate of redo procedures was substantially lower
han that previously reported for this technique (10), perhaps
elated to the intentionally short follow-up of 12 months—by
hich time 69% of patients were arrhythmia-free after a single
blation and off medication regimen, climbing to 92% after
ultiple procedures.
Although these figures are impressive, of greater rele-
ance perhaps is the attention paid to the physiological
mpact of catheter intervention. By the end of follow-up,
he primary endpoint of peak oxygen consumption had
ncreased significantly in the ablation arm and decreased in
he rate control arm, with close attention paid by the
nvestigators to exclude any influence of subject motivation
y incorporating the respiratory exchange ratio to standard-
ze exercise effort. For each of the secondary endpoints, a
atheter ablation strategy repeatedly showed a more mark-
dly positive response from baseline than a rate control
w
t
o
c
r
a
w
d
u
s
s
(
F
s
s
a
f
p
H
C
v
D
R
C
F
t
c
A
r
g
t
m
e
n
J
i
e
i
1905JACC Vol. 61, No. 18, 2013 O’Neill
May 7, 2013:1904–5 Ablation of Persistent AF in HFstrategy although not always reaching statistical significance.
Therefore, the investigators can reasonably conclude that
rhythm control by catheter ablation in their laboratory is
more effective than good rate control in the studied popu-
lation of patients with medically optimized HF.
How readily can these results be generalized to the ever-
increasing population of patients with symptomatic HF and
AF? The investigators openly acknowledge some important
limitations of their study. For example, their small cohort is
young, and two-thirds of patients have a nonischemic etiology
for their HF. Over the course of the trial, only 52 of 101
patients referred for participation underwent randomization,
with no mention of the denominator of the HF population
from which the studied cohort was recruited. It might be seen
as unusual that neither a failed trial of cardioversion nor
inadequate rate-control were specified as inclusion criteria. It is
common clinical practice to offer a therapeutic trial of sinus
rhythm by means of cardioversion or to demonstrate an
inability to achieve adequate pharmacological rate control
before embarking on what is likely to be more than 1 catheter
ablation procedure in such a challenging population. In fact,
only 14 of 26 (54%) of the ablation arm and 15 of 26 (58%) of
the rate control arm had undergone a previous cardioversion.
Similarly, 14 of 26 (54%) rate control patients were already
rate-controlled at baseline and required no further change in
medication throughout the study. In defense of the investiga-
tors, however, this was designed as a trial of rate versus rhythm
control as pre-specified strategies for symptomatic patients
with no further treatment needed for adequately rate-
controlled patients at inclusion.
As always, the issue of procedural complications merits empha-
sis. These were very extensive ablation procedures (333 61 min),
ith high fluoroscopy (80 19 min) and ablation (82 20 min)
imes. One patient required a sternotomy for tamponade, and 3
ther significant complications were reported, giving a reported
omplication rate of 4 in 30 procedures (13%). Although the
eported maintenance of sinus rhythm at 1 year is high, gradual
ttrition will likely occur, as has been widely reported for patients
ith persistent AF (11), necessitating a very frank and thorough
iscussion with patients at the outset about the potential risk and
nproven longerterm benefits of such an aggressive interventional
trategy.
Conventional rhythm control strategies have not been
hown to offer a mortality benefit over rate control in HF
4). A recently published substudy of the AF-CHF (Atrial
ibrillation and Congestive Heart Failure) trial demon-
trated a modestly greater improvement in quality of life
cores with a rhythm compared with rate control strategy
nd a greater likelihood of New York Heart Association
unctional class improvement associated with a higher
revalence of sinus rhythm (12). The electrophysiology and
F communities eagerly await the outcome of the
ASTLE-AF (Catheter Ablation Versus Standard Con-
entional Treatment in Patients With Left Ventricular
ysfunction and Atrial Fibrillation) and RAFT AF (A
andomized Ablation-based Atrial Fibrillation Rhythm control Versus Rate Control Trial in Patients With Heart
ailure and High Burden Atrial Fibrillation) trials, both due
o complete in 2016, and both of which address the role of
atheter ablation versus medical therapy for management of
F in substantially larger numbers of HF patients than
eported in the current study. Although this is a challenging
roup of patients, it is also potentially the group that stands
o gain the most in terms of morbidity and perhaps even
ortality. In the meantime, the advice must remain to assess
ach HF patient on an individual basis when considering a
onpharmacological rhythm control strategy. The study by
ones et al. is to be enthusiastically commended for extend-
ng our evidence base to persistent AF and in particular for
mbracing a study design that has clearly been jointly
nformed by experts in electrophysiology and HF medicine.
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